Sign in
CNTX Stock Price, Chart, Stats & News
Context Therapeutics Inc.
Save
Context Therapeutics Inc. (CNTX) does not currently pay a dividend.
31.76M
Market cap
–
Current P/E
–
Forward P/E
CNTX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -52.74% |
ROE | -47.04% |
D/E | 0.00x |
Interest coverage ratio | – |
CNTX valuation
P/E | – |
P/S | – |
P/B | 3.94x |
P/CF | -10.59x |
P/FCF | -10.57x |
P/OCF | -10.59x |
PEG | 0.25x |
EV multiple | -7.84x |
About
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Similar securities
Based on sector and market capitalization
Report issue